Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss. - Fedoriw A; Rajapurkar SR; O'Brien S; Gerhart SV; Mitchell LH; Adams ND; Rioux N; Lingaraj T; Ribich SA; Pappalardi MB; Shah N; Laraio J; et al. (Cancer cell, 2019)